Cross-platform genomic identification and clinical validation of breast cancer diagnostic biomarkers
Dongdong Liu, Beibei Li, Xiaoshun Shi, Jiexia Zhang, Allen Chen, Jiarui Xu, Wan Wang, Kailing Huang, Jinwei Gao, Zhouxia Zheng, Dan Liu, Huimin Wang, Wen Shi, Lin Chen, Jianhua Xu
Abstract
INTRODUCTION: Circulating non-coding RNA is an ideal source to discover novel biomarkers for non-invasive screening. However, studies for the discovery of universal miRNAs in serum and exosomes for breast cancer early diagnosis are limited. METHODS: studies were performed to understand the role of identified hsa-miR-423-5p in cancer proliferation, migration, cancer stem cell properties. Next, global non-coding RNA expression profiles in blood serum and exosome were performed. hsa-miR-423-5p expression from a total of 356 peripheral blood samples was evaluated and the association of hsa-miR-423-5p expression with clinical characteristics, sensitivity and specificity for breast cancer diagnosis were assessed. RESULTS: . Compared with 113 healthy women, quantification analysis of hsa-miR-423-5p in 224 breast cancer samples confirmed the abnormal expression. Serum hsa-miR-423-5p was significantly associated with the clinical stage (P=0.001) and Ki-67 level (P=0.004). CONCLUSIONS: , and clinical samples reveal that hsa-miR-423-5p could be used as a non-invasive breast cancer biomarker.